LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
28.57
+0.14 (0.49%)
Nov 5, 2024, 3:49 PM EST - Market open
Company Description
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States.
Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia.
The company is headquartered in Del Mar, California.
LENZ Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Evert Schimmelpennink |
Contact Details
Address: 445 Marine View Avenue, Suite 320 Del Mar, California 92014 United States | |
| Phone | (858) 925-7000 |
| Website | lenz-tx.com |
Stock Details
| Ticker Symbol | LENZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001815776 |
| ISIN Number | US52635N1037 |
| Employer ID | 84-4867570 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Evert B. Schimmelpennink | President, Chief Executive Officer, Secretary and Director |
| Shawn Olsson | Chief Commercial Officer |
| Marc G. Odrich M.D. | Chief Medical Officer |
| James W. McCollum | Co-Founder and Director |
| Daniel R. Chevallard CPA | Chief Financial Officer |
| Domenick Porfidia | Vice President of Sales |
| David Murphy | Vice President of Marketing |
| Breianna Bowen | Vice President of Human Resources |
| Marvin J. Garrett | Senior Vice President of Regulatory and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2024 | 424B3 | Prospectus |
| Oct 28, 2024 | 424B3 | Prospectus |
| Oct 28, 2024 | 8-K | Current Report |
| Sep 19, 2024 | EFFECT | Notice of Effectiveness |
| Sep 19, 2024 | 424B3 | Prospectus |
| Sep 13, 2024 | UPLOAD | Filing |
| Sep 11, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 14, 2024 | 424B3 | Prospectus |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Aug 14, 2024 | 8-K | Current Report |